Go Pro

Hims & Hers Health (HIMS) Stock Price, News & Analysis

Hims & Hers Health logo
$28.10 -4.64 (-14.16%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$28.12 +0.02 (+0.07%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Hims & Hers Health Stock (NYSE:HIMS)

Advanced

Key Stats

Today's Range
$27.93
$34.57
50-Day Range
$22.25
$38.34
52-Week Range
$13.74
$70.43
Volume
28.37 million shs
Average Volume
13.46 million shs
Market Capitalization
$6.50 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.43
Consensus Rating
Hold

Company Overview

Hims & Hers Health Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
59th Percentile Overall Score

HIMS MarketRank™: 

Hims & Hers Health scored higher than 59% of companies evaluated by MarketBeat, and ranked 198th out of 837 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Hims & Hers Health has received a consensus rating of Hold. The company's average rating score is 2.19, and is based on no strong buy ratings, 4 buy ratings, 11 hold ratings, and 1 sell rating.

  • Upside Potential

    Hims & Hers Health has a consensus price target of $31.43, representing about 11.9% upside from its current price of $28.10.

  • Amount of Analyst Coverage

    Hims & Hers Health has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Hims & Hers Health's stock forecast and price target.
  • Earnings Growth

    Earnings for Hims & Hers Health are expected to grow by 1,633.33% in the coming year, from $0.03 to $0.52 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Hims & Hers Health is -312.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Hims & Hers Health is -312.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Hims & Hers Health has a PEG Ratio of 92.14. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Hims & Hers Health has a P/B Ratio of 11.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Hims & Hers Health's valuation and earnings.
  • Percentage of Shares Shorted

    30.07% of the float of Hims & Hers Health has been sold short.
  • Short Interest Ratio / Days to Cover

    Hims & Hers Health has a short interest ratio ("days to cover") of 4.52.
  • Change versus previous month

    Short interest in Hims & Hers Health has recently increased by 0.40%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Hims & Hers Health does not currently pay a dividend.

  • Dividend Growth

    Hims & Hers Health does not have a long track record of dividend growth.

  • News Sentiment

    Hims & Hers Health has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 19 news articles for Hims & Hers Health this week, compared to 10 articles on an average week.
  • Search Interest

    Only 75 people have searched for HIMS on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.
  • MarketBeat Follows

    24 people have added Hims & Hers Health to their MarketBeat watchlist in the last 30 days. This is an increase of 14% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Hims & Hers Health insiders have sold 131.20% more of their company's stock than they have bought. Specifically, they have bought $1,172,732.00 in company stock and sold $2,711,339.00 in company stock.

  • Percentage Held by Insiders

    11.76% of the stock of Hims & Hers Health is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    63.52% of the stock of Hims & Hers Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Hims & Hers Health's insider trading history.
Receive HIMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hims & Hers Health and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HIMS Stock News Headlines

Hims & Hers down as FDA advisors snub first peptide
Hims & Hers Health Slides as Traders Fade Peptide Rally
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
Why Is HIMS Stock Rallying 13% Today?
Hims and Hers Health logo displayed alongside branded personal care product bottles on bathroom countertops.
As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner
Hims & Hers Health shares have surged 45% in 30 days on GLP-1 coverage shifts, but overbought technicals, a Hold rating, and rising short interest suggest a pullback may be near.
Hims & Hers Health (NYSE:HIMS) CFO Sells 7,163 Shares
See More Headlines

HIMS Stock Analysis - Frequently Asked Questions

Hims & Hers Health's stock was trading at $32.45 on January 1st, 2026. Since then, HIMS shares have decreased by 13.4% and is now trading at $28.1030.

Hims & Hers Health, Inc. (NYSE:HIMS) issued its quarterly earnings results on Monday, May, 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by $0.44. The company's quarterly revenue was up 3.8% on a year-over-year basis.
Read the conference call transcript
.

Hims & Hers Health's board approved a stock buyback plan on Monday, November 17th 2025, which authorizes the company to repurchase $250,000,000 in shares, according to EventVestor. This means that the company could buy up to 3% of its stock through open market purchases. Stock buyback plans are often a sign that the company's board believes its shares are undervalued.

Hims & Hers Health's top institutional shareholders include Handelsbanken Fonder AB (0.03%), Stonekeep Investments LLC (0.01%), FNY Investment Advisers LLC and Valeo Financial Advisors LLC. Insiders that own company stock include Melissa Baird, Michael Chi, Soleil Boughton, Oluyemi Okupe, David B Wells, Patrick Harrison Carroll, Christopher D Payne, Andrew Dudum, Garcia Andrea G Perez, Christiane Pendarvis, Irene Becklund, Irene Becklund, Deborah M Autor, Anja Manuel and Lynne Chou O'keefe.
View institutional ownership trends
.

Shares of HIMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Hims & Hers Health investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
5/11/2026
Today
7/24/2026
Next Earnings (Estimated)
8/10/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MEDICAL INFO SYS
Sub-Industry
Healthcare
Current Symbol
NYSE:HIMS
CIK
1773751
Fax
N/A
Employees
2,442
Year Founded
2017

Price Target and Rating

High Price Target
$60.00
Low Price Target
$21.00
Potential Upside/Downside
+11.9%
Consensus Rating
Hold
Rating Score (0-4)
2.19
Research Coverage
16 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.09)
Trailing P/E Ratio
N/A
Forward P/E Ratio
936.77
P/E Growth
92.14
Net Income
$128.37 million
Net Margins
-0.56%
Pretax Margin
-1.61%
Return on Equity
6.10%
Return on Assets
1.52%

Debt

Debt-to-Equity Ratio
2.18
Current Ratio
1.69
Quick Ratio
1.56

Sales & Book Value

Annual Sales
$2.37 billion
Price / Sales
2.74
Cash Flow
$0.72 per share
Price / Cash Flow
39.12
Book Value
$2.38 per share
Price / Book
11.81

Miscellaneous

Outstanding Shares
231,458,000
Free Float
204,239,000
Market Cap
$6.50 billion
Optionable
Optionable
Beta
2.35

Social Links

7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NYSE:HIMS) was last updated on 7/25/2026 by MarketBeat.com Staff.
From Our Partners